ensitrelvir - Profile
✉ Email this page to a colleague
What are the generic sources for ensitrelvir and what is the scope of patent protection?
Ensitrelvir
is the generic ingredient in one branded drug marketed by Shionogi and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ensitrelvir has sixty patent family members in twenty-eight countries.
Summary for ensitrelvir
| International Patents: | 60 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ensitrelvir
Generic Entry Date for ensitrelvir*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ensitrelvir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
